Long-term symptoms after SARS-CoV-2 infection in school children: population-based cohort with 6-months follow-up

INTRODUCTION

Children can suffer from SARS-CoV-2 postviral syndromes, but it is yet unclear to what extent children are affected by long COVID (i.e., symptoms that continue for more than 12 weeks and are not explained by an alternative diagnosis).¹ Current evidence is predominantly limited to selective – mostly clinical – populations without control groups^2–5, which do not allow estimating the overall prevalence and burden in a general pediatric population. In this study, we compared long COVID related symptoms in children and adolescents (hereafter referred to as children) with 6-months follow-up according to their SARS-CoV-2 serology.

METHODS

The Ciao Corona study is a longitudinal cohort investigating SARS-CoV-2 seroprevalence and clustering of cases among around 2500 children from 55 randomly selected primary and secondary schools in the canton of Zurich (about 1.5 million inhabitants) in Switzerland (study design described elsewhere⁶). Between June 2020 and April 2021, we completed three testing phases where we collected venous blood for serological analysis and asked about symptoms with online questionnaires. For serological analysis, we used the ABCORA 2.0 test.⁶

In this analysis, we compared children who tested positive for SARS-CoV-2 antibodies in October/November 2020 with those who tested negative. Children who were seronegative in October/November 2020 and seroconverted or were not retested by March/April 2021 were excluded from the analysis (n=256). In March-May 2021 we assessed the presence of symptoms occurring since October 2020 and lasting for at least 4 weeks³, and persisting for either >4 weeks or >12 weeks.

Descriptive analysis was performed with R version 4.0.3. The Ethics Committee of the Canton of Zurich, Switzerland (2020-01336) approved the study and parents/legal guardians provided written informed consent.

RESULTS

Overall, 1355 of 2503 children with a serology result in October/November 2020 and follow up questionnaire in March/April 2021 were included. Participant characteristics, symptoms and self-rated health are summarized in the Table. Among seropositive and seronegative children, 9% versus 10% reported at least one symptom beyond 4 weeks, and 4% versus 2% at least one symptom beyond 12 weeks (Table). None of the seropositive children reported hospitalization after October 2020. The distribution of pre-existing chronic diseases among seropositive (n=109) and seronegative children (n=1246) is given in Supplemental Table S1. Participant characteristics, symptoms and self-rated health for a subpopulation of seropositive (n=89) and seronegative children (n=891) without chronic disease is shown in Table S2.

DISCUSSION

This study suggests a very low prevalence of long COVID in a randomly selected population-based cohort of children followed over 6 months after serological testing. Seropositive children, all with a history of pauci-symptomatic SARS-CoV-2 infection, did not report long COVID more frequently than seronegative children.

While nobody doubts the existence of even severe forms of long COVID in children⁴, the estimates on prevalence range from 95% of children reporting symptoms within 8 months of follow-up³, to 1.8% of schoolchildren at 2 months in a large surveillance² or to full recovery in all children with predominantly mild disease⁵. Initial SARS-CoV-2 infection severity, different methodological approaches (clinical assessment versus self-report), definition of cases (diagnosed versus suspected cases), variable follow-up times, and prevalence of pre-existing clinical conditions likely contribute to the variability of long COVID reported in children. Longitudinal data on large population-based samples are needed to better understand its potential impact on health-related quality of life and activities in daily living including going to school.

Strengths of our study include the large, representative, randomly selected sample of school children and inclusion of a population-based seronegative control group that could be ensured thanks to the longitudinal design. Limitations include the relatively small number of seropositive children, possible misclassification of some false seropositive children, potential recall bias, parental report of child’s symptoms, and lack of information on symptom severity.

FUNDING

This study is part of the Corona Immunitas research network, coordinated by the Swiss School of Public Health (SSPH+), and funded by fundraising of SSPH+ that includes funds of the Swiss Federal Office of Public Health and private funders (ethical guidelines for funding stated by SSPH+ were respected), by funds of the cantons of Switzerland (Vaud, Zurich, and Basel), and by institutional funds of the universities. Additional funding, specific to this study, was available from the University of Zurich Foundation. The funder/sponsor did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All authors had full access to all data analysis outputs (reports and tables) and take responsibility for their integrity and accuracy.